

Singapore's Everlife Holdings appoints Ramesh Subrahmanian as Board of Directors

July 2, 2021 | News

New leadership will extend Everlife's medical devices, laboratory equipment and consumables markets and product segments in Asia



Everlife Holdings Pte. Ltd., a leading manufacturer and distributor of medical devices and laboratory equipment and consumables in Asia, has appointed Ramesh Subrahmanian to the company's Board of Directors.

In his new role as a member of the Board at Everlife, Ramesh will support the development of the company's strategic plan including defining the key growth levers, acquisitions, digital footprint, and organizational construct. New leadership will help in shaping and refining strategic and digital roadmap while the company builds future organization model in a plans to integrate with multiple acquisitions over the next 12-18 months.

Ramesh is a seasoned leader in the healthcare industry with over 25 years of global senior management experience in the pharmaceuticals, vaccines, and medical devices sectors. He currently serves on the Board of Directors at Healthium, while also managing his own advisory firm Alchemy Advisors, which helps global clients optimise their growth strategies and organisation models to deliver superior performance.

Prior to joining Everlife, Ramesh was the President of International Operations for Acelity (a global leader in wound care), lead Merck's APAC pharma business, and served as International Group President at Stryker (medical technology company). He led the transformation of the European business, developed an aggressive growth strategy for the emerging markets for orthopedic business in China. He also served as Chairman of PhRMA's Asia Committee and was a founding Board member of the Asia Pacific Medical Technology Association ("APACMed"), of which Everlife is also a member.

Ramesh's deep operating experience and strategic agility will help accelerate Everlife's journey to becoming the leading medical device platform in South East Asia and India" says Dr. Arjun Oberoi, Executive Chairman, Everlife.

Everlife currently operates in 6 countries through its investments in CPC Diagnostics, an India based manufacturer and marketer of in-vitro diagnostic products; Chemopharm Group, a leading provider of products and solutions to laboratory, research, and medical facilities in Malaysia and across South-East Asia; DV Medika, a leading manufacturer and distributor of hospital furniture, imaging systems, and critical care equipment in Indonesia and Lifeline Diagnostics, the leading distributor of in-vitro diagnostics and life science products in the Philippines.